AAPL280.57+5.42 (+1.97%) ▲|ABBV247.06+3.92 (+1.61%) ▲|ABT94.32+1.08 (+1.16%) ▲|ACN128.65+2.83 (+2.25%) ▲|ADBE200.95+7.54 (+3.90%) ▲|AMAT643.68-24.32 (-3.64%) ▼|AMD518.19-14.39 (-2.70%) ▼|AMGN356.26+3.44 (+0.98%) ▲|AMT175.26+6.54 (+3.88%) ▲|AMZN231.03+4.02 (+1.77%) ▲|AVGO368.95-9.96 (-2.63%) ▼|AXP341.11-1.35 (-0.39%) ▼|BA218.67+0.55 (+0.25%) ▲|BAC57.85-0.34 (-0.58%) ▼|BKNG182.67+5.62 (+3.17%) ▲|BLK976.68+4.76 (+0.49%) ▲|BMY57.13+1.74 (+3.13%) ▲|BNY143.84-1.59 (-1.09%) ▼|BRK-B496.45+8.64 (+1.77%) ▲|C141.63-3.35 (-2.31%) ▼|CAT1,008.04-48.97 (-4.63%) ▼|CL90.91-0.15 (-0.16%) ▼|CMCSA23.19+0.50 (+2.18%) ▲|COF204.63-0.28 (-0.13%) ▼|COP105.26-1.15 (-1.08%) ▼|COST954.77+12.53 (+1.33%) ▲|CRM157.24+7.05 (+4.69%) ▲|CSCO115.55-3.43 (-2.88%) ▼|CVS104.49-0.17 (-0.16%) ▼|CVX170.77-1.47 (-0.85%) ▼|DE626.69-4.07 (-0.65%) ▼|DHR193.30+0.49 (+0.25%) ▲|DIS98.66+0.61 (+0.62%) ▲|DUK128.07+0.96 (+0.76%) ▲|EMR143.94-1.41 (-0.97%) ▼|FDX323.26-6.18 (-1.88%) ▼|GD347.02+2.32 (+0.67%) ▲|GE369.19-2.17 (-0.58%) ▼|GEV1,050.51-34.96 (-3.22%) ▼|GILD126.97+3.13 (+2.53%) ▲|GM78.60+0.07 (+0.09%) ▲|GOOG339.89-2.31 (-0.67%) ▼|GOOGL340.95-2.76 (-0.80%) ▼|GS1,027.62-37.47 (-3.52%) ▼|HD348.64+3.64 (+1.06%) ▲|HON231.65+0.41 (+0.18%) ▲|IBM269.62+11.35 (+4.39%) ▲|INTC127.78-5.09 (-3.83%) ▼|INTU269.52+14.45 (+5.67%) ▲|ISRG405.18+5.49 (+1.37%) ▲|JNJ253.62+8.74 (+3.57%) ▲|JPM329.70-5.42 (-1.62%) ▼|KO82.16+1.74 (+2.16%) ▲|LIN521.08-1.20 (-0.23%) ▼|LLY1,209.50+81.81 (+7.25%) ▲|LMT511.19+6.17 (+1.22%) ▲|LOW221.91-0.03 (-0.01%) ▼|LRCX379.55-22.27 (-5.54%) ▼|MA502.43+13.51 (+2.76%) ▲|MCD268.37+3.83 (+1.45%) ▲|MDLZ61.49+0.29 (+0.47%) ▲|MDT80.83+1.03 (+1.29%) ▲|META554.88+12.01 (+2.21%) ▲|MMM165.46-2.51 (-1.49%) ▼|MO73.50+0.29 (+0.40%) ▲|MRK127.63+2.18 (+1.74%) ▲|MS212.76-8.28 (-3.74%) ▼|MSFT371.22+18.39 (+5.21%) ▲|MU1,146.00-67.56 (-5.57%) ▼|NEE87.79+0.09 (+0.10%) ▲|NFLX74.13+3.23 (+4.56%) ▲|NKE41.04+0.14 (+0.34%) ▲|NOW97.26+7.74 (+8.65%) ▲|NVDA194.24-1.50 (-0.77%) ▼|ORCL150.22-2.24 (-1.47%) ▼|PEP141.45+1.93 (+1.38%) ▲|PFE24.22+0.55 (+2.30%) ▲|PG149.03+0.53 (+0.36%) ▲|PLTR113.18+5.91 (+5.51%) ▲|PM181.10+2.17 (+1.21%) ▲|QCOM196.55-8.35 (-4.08%) ▼|RTX189.19+2.60 (+1.39%) ▲|SBUX104.49+1.33 (+1.29%) ▲|SCHW89.76+0.32 (+0.36%) ▲|SO96.96+1.05 (+1.09%) ▲|SPG226.74+1.25 (+0.55%) ▲|T22.58+0.16 (+0.71%) ▲|TMO504.85-0.90 (-0.18%) ▼|TMUS183.94+2.37 (+1.30%) ▲|TSLA383.17+8.05 (+2.15%) ▲|TXN293.68-18.13 (-5.81%) ▼|UBER76.13+3.88 (+5.36%) ▲|UNH424.58+9.05 (+2.18%) ▲|UNP269.60+1.87 (+0.70%) ▲|UPS108.86-0.46 (-0.42%) ▼|USB61.02-0.19 (-0.31%) ▼|V338.22+7.70 (+2.33%) ▲|VZ46.55+0.48 (+1.03%) ▲|WFC84.68-0.06 (-0.07%) ▼|WMT116.94+1.16 (+1.00%) ▲|XOM136.62-0.93 (-0.68%) ▼|AAPL280.57+5.42 (+1.97%) ▲|ABBV247.06+3.92 (+1.61%) ▲|ABT94.32+1.08 (+1.16%) ▲|ACN128.65+2.83 (+2.25%) ▲|ADBE200.95+7.54 (+3.90%) ▲|AMAT643.68-24.32 (-3.64%) ▼|AMD518.19-14.39 (-2.70%) ▼|AMGN356.26+3.44 (+0.98%) ▲|AMT175.26+6.54 (+3.88%) ▲|AMZN231.03+4.02 (+1.77%) ▲|AVGO368.95-9.96 (-2.63%) ▼|AXP341.11-1.35 (-0.39%) ▼|BA218.67+0.55 (+0.25%) ▲|BAC57.85-0.34 (-0.58%) ▼|BKNG182.67+5.62 (+3.17%) ▲|BLK976.68+4.76 (+0.49%) ▲|BMY57.13+1.74 (+3.13%) ▲|BNY143.84-1.59 (-1.09%) ▼|BRK-B496.45+8.64 (+1.77%) ▲|C141.63-3.35 (-2.31%) ▼|CAT1,008.04-48.97 (-4.63%) ▼|CL90.91-0.15 (-0.16%) ▼|CMCSA23.19+0.50 (+2.18%) ▲|COF204.63-0.28 (-0.13%) ▼|COP105.26-1.15 (-1.08%) ▼|COST954.77+12.53 (+1.33%) ▲|CRM157.24+7.05 (+4.69%) ▲|CSCO115.55-3.43 (-2.88%) ▼|CVS104.49-0.17 (-0.16%) ▼|CVX170.77-1.47 (-0.85%) ▼|DE626.69-4.07 (-0.65%) ▼|DHR193.30+0.49 (+0.25%) ▲|DIS98.66+0.61 (+0.62%) ▲|DUK128.07+0.96 (+0.76%) ▲|EMR143.94-1.41 (-0.97%) ▼|FDX323.26-6.18 (-1.88%) ▼|GD347.02+2.32 (+0.67%) ▲|GE369.19-2.17 (-0.58%) ▼|GEV1,050.51-34.96 (-3.22%) ▼|GILD126.97+3.13 (+2.53%) ▲|GM78.60+0.07 (+0.09%) ▲|GOOG339.89-2.31 (-0.67%) ▼|GOOGL340.95-2.76 (-0.80%) ▼|GS1,027.62-37.47 (-3.52%) ▼|HD348.64+3.64 (+1.06%) ▲|HON231.65+0.41 (+0.18%) ▲|IBM269.62+11.35 (+4.39%) ▲|INTC127.78-5.09 (-3.83%) ▼|INTU269.52+14.45 (+5.67%) ▲|ISRG405.18+5.49 (+1.37%) ▲|JNJ253.62+8.74 (+3.57%) ▲|JPM329.70-5.42 (-1.62%) ▼|KO82.16+1.74 (+2.16%) ▲|LIN521.08-1.20 (-0.23%) ▼|LLY1,209.50+81.81 (+7.25%) ▲|LMT511.19+6.17 (+1.22%) ▲|LOW221.91-0.03 (-0.01%) ▼|LRCX379.55-22.27 (-5.54%) ▼|MA502.43+13.51 (+2.76%) ▲|MCD268.37+3.83 (+1.45%) ▲|MDLZ61.49+0.29 (+0.47%) ▲|MDT80.83+1.03 (+1.29%) ▲|META554.88+12.01 (+2.21%) ▲|MMM165.46-2.51 (-1.49%) ▼|MO73.50+0.29 (+0.40%) ▲|MRK127.63+2.18 (+1.74%) ▲|MS212.76-8.28 (-3.74%) ▼|MSFT371.22+18.39 (+5.21%) ▲|MU1,146.00-67.56 (-5.57%) ▼|NEE87.79+0.09 (+0.10%) ▲|NFLX74.13+3.23 (+4.56%) ▲|NKE41.04+0.14 (+0.34%) ▲|NOW97.26+7.74 (+8.65%) ▲|NVDA194.24-1.50 (-0.77%) ▼|ORCL150.22-2.24 (-1.47%) ▼|PEP141.45+1.93 (+1.38%) ▲|PFE24.22+0.55 (+2.30%) ▲|PG149.03+0.53 (+0.36%) ▲|PLTR113.18+5.91 (+5.51%) ▲|PM181.10+2.17 (+1.21%) ▲|QCOM196.55-8.35 (-4.08%) ▼|RTX189.19+2.60 (+1.39%) ▲|SBUX104.49+1.33 (+1.29%) ▲|SCHW89.76+0.32 (+0.36%) ▲|SO96.96+1.05 (+1.09%) ▲|SPG226.74+1.25 (+0.55%) ▲|T22.58+0.16 (+0.71%) ▲|TMO504.85-0.90 (-0.18%) ▼|TMUS183.94+2.37 (+1.30%) ▲|TSLA383.17+8.05 (+2.15%) ▲|TXN293.68-18.13 (-5.81%) ▼|UBER76.13+3.88 (+5.36%) ▲|UNH424.58+9.05 (+2.18%) ▲|UNP269.60+1.87 (+0.70%) ▲|UPS108.86-0.46 (-0.42%) ▼|USB61.02-0.19 (-0.31%) ▼|V338.22+7.70 (+2.33%) ▲|VZ46.55+0.48 (+1.03%) ▲|WFC84.68-0.06 (-0.07%) ▼|WMT116.94+1.16 (+1.00%) ▲|XOM136.62-0.93 (-0.68%) ▼|
25.8 C
New York
Friday, June 26, 2026

Tag: FDA

newssourceFORcompanyinformationcontent1marketreleases

Parent Project Muscular Dystrophy Announces Children’s Hospital of Philadelphia as Certified Duchenne Care Center, Recipient of Inaugural Clinical Research Designation

WASHINGTON, June 12, 2025 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), is...

European Commission Grants Orphan Drug Designation to Florbetaben (18F) for Diagnosis of ATTR Amyloidosis

Florbetaben (18F) has been granted Orphan drug designation for the diagnosis of ATTR amyloidosisFlorbetaben (18F) previously received orphan drug designation as a diagnostic agent...

Lunit AI Used Again for Mass Screening During 2025 Hajj Season in Saudi Arabia

Saudi Government and Seha Virtual Hospital selected Lunit INSIGHT CXR to detect respiratory diseases among millions of pilgrims, supporting Saudi Arabia's Vision 2030 healthcare strategy SEOUL,...

As Public Cancer Funding Wavers, Oncology’s Brightest Breakthroughs Are Coming From Industry

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /CNW/ -- Equity Insider News Commentary – The 2025 ASCO...

Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development

SALT LAKE CITY, June 12, 2025 /PRNewswire/ -- Rebel Medicine Inc, a clinical‑stage biotechnology company developing innovative drug delivery systems and non‑opioid pain therapeutics...

Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease

SUMMIT, N.J., June 12, 2025 /PRNewswire/ -- Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, announced today that...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

WILMINGTON, Del., June 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, and HOPE...

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025.

Angitia Biopharmaceuticals Announces Topline Results from First in Human Study of AGA2115, A Bispecific Antibody for the Treatment of Osteogenesis Imperfecta

- AGA2115 also received Orphan Drug Designation from European Medicines Agency 
- AGA2115 also received Orphan Drug Designation from European Medicines Agency

Reacta Healthcare announces transformation into a facility for multi-allergen manufacturing

1st production of pharmaceutical grade egg and milk challenge mealsProduct portfolio of challenge meals now includes peanut, milk and eggInnovation pipeline includes development of...

ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028

LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug...

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS)...

MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications

PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor,...

Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma

Paris, France – June 12, 2025

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFDA

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers